JAMA Oncology’s Post

Here is our latest published article. In this work, we investigated the anti-acute myeloid leukemia (AML) activity of bortezomib (BTZ), emphasizing its potential against leukemia stem cells (LSC), using KG-1a cells, an AML cell line with stem-like properties. We found that BTZ reduces the number of AML stem-like cells via NF-κB inhibition and the induction of oxidative stress. https://lnkd.in/dDHPyqwr

UK’s NICE Endorses Brukinsa as Treatment for Chronic Lymphocytic Leukemia NICE has endorsed Brukinsa as a treatment for adults with untreated Chronic Lymphocytic Leukemia (CLL) if they have a certain genetic mutation. It is also recommended for adults with untreated CLL who cannot take other treatments, as well as for relapsed or refractory CLL. Brukinsa is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) and is being evaluated for other B-cell malignancies. This endorsement is significant for CLL patients in the UK and highlights the importance of innovative and cost-effective therapies in improving patient outcomes in oncology. For more details please click the link! https://lnkd.in/diQnKaxc #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

https://lnkd.in/dx-nasYB Key Insights: • Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) are conditions where abnormal blood cells originate from either B or T cells. According to the 2017 classification system of the World Health Organization (WHO), these conditions fall into the category of precursor lymphoid neoplasms Visit MedicoInsights to explore key insights #jazzpharmaceuticals #leukemia #cancer #knowledge #HealthTrends #Insights #HealthIndustry #HealthInnovation #latestnews #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights #news #pharma #health #dailynews

The RNA helicase U5 snRNP200 proposed as a novel tumor associated antigen on acute myeloid leukemia cells. #aml https://lnkd.in/gxXpsugu

.....#Breyanzi on Thursday won an FDA accelerated approval for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), BMS said. To be eligible for the CD19-targeted CAR-T med, a patient must have tried a BTK drug such as Brukinsa and a BCL2 inhibitor such as AbbVie and Roche’s Venclexta. Breyanzi is the first CAR-T cell therapy to enter the CLL/SLL field, where BTK inhibitors are standard first-line treatments.... Bristol Myers Squibb #acceleratedapproval #CLL #leukemia #lymphoma #cd19 #carttherapies #cartcells #SLL #celltherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #healthcare #lifesciences #biotech #biotechnology #pharma #pharmaceuticals #BTKdrug

AstraZeneca’s blockbuster BTK inhibitor Calquence significantly improved progression-free survival when used as a frontline treatment in patients with mantle cell lymphoma. Data for overall survival was not yet mature at the time of the interim analysis, but AstraZeneca noted in its announcement that “a trend was observed in favor of Calquence plus chemoimmunotherapy.” ECHO will continue as planned to assess OS. Thursday’s late-stage readout comes a year after AbbVie and J&J voluntarily pulled the accelerated MCL approval for their BTK blocker Imbruvica. While data from Phase III confirmatory trials showed that Imbruvica can significantly improve PFS versus placebo, the treatment yielded no significant benefit in terms of OS and complete response. #biotech #biopharma #Lymphoma #BTK #Calquence

THP-1 cells, a human monocytic leukemia cell line, have become indispensable tools in the study of leukemia, offering valuable insights into disease mechanisms, drug discovery, and therapeutic strategies. This article explores the role of THP-1 cells in leukemia research, highlighting their applications and contributions to advancing our understanding of this complex disease. Understanding #cells #Leukemia #research #THP1

THP-1 cells, a human monocytic leukemia cell line, have become indispensable tools in the study of leukemia, offering valuable insights into disease mechanisms, drug discovery, and therapeutic strategies. This article explores the role of THP-1 cells in leukemia research, highlighting their applications and contributions to advancing our understanding of this complex disease. Understanding #cells #Leukemia #research #THP1

Covalent BTK Inhibitors: A Review of the Evidence in Chronic Lymphocytic Leukemia: This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents. #finance #pharmacy #lifesciences